Emmessar Biotech Peer Comparison

BSE: 524768

₹24.99

₹0.61 (2.50%)

As on 28-Aug-2026IST

Market cap

₹13 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

32.3

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	13	21,529	19,158	17,862	18,168
Revenue (₹ Cr)	0	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	0.39	735.15	678.07	169.62	666.92
Net Margin (%)	16.48	26.88	28.10	6.90	20.60
RoE (%)	4.87	19.16	19.73	20.76	18.75
Price to Earnings	32.30	29.29	28.79	105.31	28.22
Price-To-Book	1.54	4.88	5.09	19.75	4.49

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	0.34	2,569.77	2,287.33	2,432.06	3,229.67
Total Income	2.38	2,735.39	2,413.29	2,458.54	3,237.12
Total Expenditure	1.77	1,628.14	1,490.75	2,202.20	2,090.06
EBITDA	-1.43	941.63	796.58	229.86	1,139.61
Depreciation	0.10	57.58	78.10	17.24	281.06
EBIT	-1.53	884.05	718.48	212.62	858.55
Interest	0.00	7.69	0.88	5.72	190.64
Other Income	2.04	165.62	125.96	26.48	7.45
Exceptional Items	0.00	-49.16	0.00	-5.13	-17.24
Profit before Tax	0.51	992.82	843.56	228.25	658.12
Provision for Tax	0.12	257.67	165.49	58.63	-8.80
Profit after Tax	0.39	735.15	678.07	169.62	666.92

Liabilities (₹ Cr)

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	8.12	4,202.90	3,586.42	872.79	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	1.03	91.50	28.74	134.50	1,392.75
Current Liabilities	0.39	627.48	385.94	981.81	2,077.10
Total Liabilities	9.42	4,911.11	3,207.85	1,879.19	6,862.28

Assets (₹ Cr)

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	1.72	770.28	1,291.22	42.47	5,617.77
Current Assets	7.81	3,803.22	2,585.66	1,739.93	1,539.85
Total Assets	9.42	4,911.11	3,207.85	1,879.19	6,862.28
Total Debt*	0.00	2.50	0.55	0.00	2,421.66
Net Current Assets	7.42	3,175.74	2,199.72	758.12	-537.25
Contingent Liabilities	--	363.79	0.64	98.41	64.29

Cashflow (₹ Cr)

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	0.22	659.75	432.37	65.36	1,065.01
Cash Flow from Investing Activities	-0.23	-71.34	-334.73	30.80	-79.97
Cash from Financing Activities	0.00	-205.34	-38.32	-65.59	-881.32
Net Cash Inflow / Outflow	0.00	383.07	59.32	30.57	103.72

Ratios

Profitability Ratios

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	12.63	26.21	26.22	21.29	13.59
ROE (%)	4.87	19.16	19.73	20.76	18.75
ROA (%)	4.18	14.95	18.69	9.67	9.26
EBIT Margin (%)	-454.01	34.40	31.41	8.74	26.58
Net Margin (%)	16.48	26.88	28.10	6.90	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	-46.08	10.69	15.01	31.10	9.59
EBIT Growth (%)	-44.89	24.14	18.45	-12.99	16.84
Net Profit Growth (%)	-2.00	-9.09	19.61	-7.49	62.68
EPS Growth (%)	-2.00	14.40	17.73	-18.33	67.41
Book Value Growth (%)	4.13	17.30	23.77	7.70	10.19

Valuation Ratios

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	31.07	28.13	29.04	102.59	27.55
Price / Book Value	1.48	4.92	5.13	19.69	4.49
Dividend Yield (%)	0.00	1.58	0.16	0.51	0.55
EV/EBITDA	-3.70	19.75	23.13	75.50	17.88
Market Cap (₹ Cr)	15.18	18,318.10	15,219.80	21,515.93	19,292.77

Solvency Ratios

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.00	0.00	0.00	0.00	0.24
Short term debt to equity ratio	--	0.00	0.00	--	0.14
Current Ratio	20.28	6.06	6.70	1.77	0.74
Quick Ratio	20.03	5.31	5.59	0.73	0.53
Interest Coverage	127.75	130.11	959.59	40.90	4.45

Operating Efficiency Ratios

	Emmessar Biotech	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	4.75	7.07	36.10	8.79	21.07
Asset Turnover	0.04	0.52	0.63	1.39	0.45
Receivable days	11.98	29.10	110.70	35.81	54.07
Inventory Days	63.60	69.53	65.86	82.25	32.16
Payable days	12.45	76.77	105.88	124.39	140.91
Cash Conversion Cycle	63.13	21.86	70.68	-6.33	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly